Connect with Asahi Kasei Pharma Corporation at Propak Asia 2024
Propak Asia 2024
AC
Asahi Kasei Pharma Corporation
Welcome to Asahi Kasei Pharma Corporation exhibiting at Propak Asia 2024
BITEC, Bangkok
11 Jun - 14 Jun, 2024
Add to Leads
Company Type
Pharmaceuticals
Product Categories
Prescription Drugs
Diagnostic Products
Product Items
TERIBONE™ (teriparatide acetate)
RECLAST™ (zoledronic acid)
ELCITONIN™ (elcatonin) Injection 20S
RECOMODULIN™ (thrombomodulin alpha)
CRESEMBA™（isavuconazonium sulfate)
DOPTELET® (avatrombopag maleate)
EMPAVELI® (pegcetacoplan)
KEVZARA® (sarilumab)
PLAQUENIL® (hydroxychloroquine sulfate)
BREDININ™ (mizoribine)
FLIVAS™ (naftopidil)
TOLEDOMIN™ (milnacipran hydrochloride)
ERIL™ (fasudil hydrochloride hydrate)
FAMVIR™ (famciclovir)
Company Overview
Asahi Kasei Pharma Corporation is a subsidiary of Asahi Kasei Corporation, specializing in the discovery, development, manufacture, and delivery of pharmaceuticals and diagnostic products. Founded in 2003, the company focuses on providing innovative healthcare solutions in fields such as musculoskeletal disorders, pain management, emergency and intensive care, and the immune system. With a commitment to improving health and quality of life, Asahi Kasei Pharma operates globally, leveraging advanced research and development capabilities.
Asahi Kasei Pharma Corporation is a subsidiary of Asahi Kasei Corporation, specializing in the discovery, development, manufacture, and delivery of pharmaceuticals and diagnostic products. Founded in 2003, the company focuses on providing innovative healthcare solutions in fields such as musculoskeletal disorders, pain management, emergency and intensive care, and the immune system. With a commitment to improving health and quality of life, Asahi Kasei Pharma operates globally, leveraging advanced research and development capabilities.